Hydra Biosciences, a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, anxiety and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms and integrated pharmacology and chemistry infrastructure enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs.
Hydra has over 75 filed patents covering the use of TRP modulators to treat diseases as well as compositions of matter and methods of use claims for specific molecules.
Hydra has raised significant financing from blue chip investors since its inception. This prominent group of investors include: Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.